FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 297 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 Is a Genomic Test Better at Finding Aggressive Prostate Cancer? October 13, 2022 CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... July 25, 2024 Immune cell count could determine whether chemotherapy is required in oropharyngeal... May 2, 2022 Load more HOT NEWS Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... Patient Guide in Testicular Cancer Now Available Also in German New on NCI’s Websites for March 2023
